Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended Marc...
April 28 2020 - 4:05PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating and developing small
molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal second quarter ended March 31, 2020, after the U.S. markets
close on May 6, 2020. Enanta management will host a conference call
at 4:30 p.m. ET to discuss these results and provide an update on
Enanta’s business, including its research and development
pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial (855)
840-0595 in the U.S. or (518) 444-4814 for international callers. A
replay of the conference call will be available starting at
approximately 7:30 p.m. ET on May 6, 2020, through 11:59 p.m. ET on
May 8, 2020 by dialing (855) 859-2056 from the U.S. or (404)
537-3406 for international callers. The passcode for both the live
call and the replay is 4261269. A live audio webcast of the
call and replay can be accessed by visiting the “Events and
Presentation” section on the “Investors” page of Enanta’s website
at www.enanta.com.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), non-alcoholic
steatohepatitis (NASH)/primary biliary cholangitis (PBC) and
hepatitis B virus (HBV). Enanta is also conducting research in
human metapneumovirus (hMPV) and emerging coronaviruses, including
SARS-CoV-2.
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta and now marketed by AbbVie as part of its
leading treatment for chronic HCV infection, is sold under the
brand names MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200428005133/en/
Media and Investor Contact: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024